OrganaBio opened a new PBMC isolation and cryopreservation facility in San Diego at Excellos Labs, targeting a key preclinical-to-clinical bottleneck for autologous cell therapy programs. The company said it can isolate and cryopreserve PBMCs within three to four hours of collection, rather than shipping live material for longer holds. OrganaBio attributed improved consistency to rapid time-to-cryopreservation, validated SOPs, and sponsor-specific processing protocols. The facility reported average PBMC viability around 99.1% and recovery above 2.9 million cells per milliliter, with batch-to-batch consistency. The operational change matters for developers because viability and functional integrity of PBMC starting material can affect downstream assays and manufacturing performance, especially for immunotherapies and certain gene therapy workflows that rely on immune cell quality.